Published in Proc Natl Acad Sci U S A on February 24, 2004
Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol (2009) 12.13
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med (2011) 7.29
Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis (2014) 3.20
Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J (2005) 3.14
Predicting linear B-cell epitopes using string kernels. J Mol Recognit (2008) 2.47
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A (2004) 2.38
The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol (2009) 2.23
Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis (2011) 2.12
Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol (2005) 2.05
Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J Virol (2005) 1.93
Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. J Virol (2006) 1.91
Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med (2006) 1.78
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol (2005) 1.72
Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev (2007) 1.68
Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China. Emerg Infect Dis (2004) 1.65
Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A (2014) 1.54
Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol (2005) 1.54
Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev (2006) 1.52
Animal models and vaccines for SARS-CoV infection. Virus Res (2007) 1.50
Monoclonal antibody-based therapies for microbial diseases. Vaccine (2009) 1.47
Clinical and laboratory findings of the first imported case of Middle East respiratory syndrome coronavirus to the United States. Clin Infect Dis (2014) 1.44
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J (2005) 1.43
A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol (2010) 1.40
Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J Virol (2004) 1.36
Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis (2005) 1.36
Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice. J Virol (2007) 1.32
Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2. J Virol (2004) 1.28
Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog (2008) 1.27
SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium. Virus Res (2007) 1.24
Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol (2005) 1.21
Identification of diverse alphacoronaviruses and genomic characterization of a novel severe acute respiratory syndrome-like coronavirus from bats in China. J Virol (2014) 1.20
Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model. Antiviral Res (2010) 1.13
Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J Virol (2014) 1.09
Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol (2005) 1.08
Respiratory viruses other than influenza virus: impact and therapeutic advances. Clin Microbiol Rev (2008) 1.05
Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. J Virol (2005) 1.03
Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol (2006) 1.02
Adaptive evolution of the spike gene of SARS coronavirus: changes in positively selected sites in different epidemic groups. BMC Microbiol (2006) 1.01
The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization. Virol J (2005) 1.00
Receptor recognition and cross-species infections of SARS coronavirus. Antiviral Res (2013) 1.00
Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin Biol Ther (2009) 0.98
Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine (2007) 0.97
Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy. Annu Rep Med Chem (2007) 0.96
Human antibody neutralizes severe Fever with thrombocytopenia syndrome virus, an emerging hemorrhagic Fever virus. Clin Vaccine Immunol (2013) 0.95
Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization. J Virol (2005) 0.93
Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. Biochem Biophys Res Commun (2008) 0.93
Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5. J Gen Virol (2011) 0.93
Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. Microbes Infect (2014) 0.91
Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccine. Proc Natl Acad Sci U S A (2005) 0.91
Lentivirus display: stable expression of human antibodies on the surface of human cells and virus particles. PLoS One (2008) 0.90
Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness. J Virol (2014) 0.89
Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus. J Virol (2012) 0.89
Direct expression and validation of phage-selected peptide variants in mammalian cells. J Biol Chem (2013) 0.88
Functional characterization of heptad repeat 1 and 2 mutants of the spike protein of severe acute respiratory syndrome coronavirus. J Virol (2006) 0.88
Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nat Struct Mol Biol (2016) 0.87
Treatment of severe acute respiratory syndrome. Eur J Clin Microbiol Infect Dis (2005) 0.87
Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol J (2010) 0.86
Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol Cancer Ther (2012) 0.85
Identification of the Receptor-Binding Domain of the Spike Glycoprotein of Human Betacoronavirus HKU1. J Virol (2015) 0.83
Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Rev Med Virol (2011) 0.83
Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library. PLoS Negl Trop Dis (2013) 0.82
Production of an anti-severe acute respiratory syndrome (SARS) coronavirus human monoclonal antibody Fab fragment by using a combinatorial immunoglobulin gene library derived from patients who recovered from SARS. Clin Vaccine Immunol (2006) 0.82
SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-kappaB pathway in human monocyte macrophages in vitro. Virus Res (2009) 0.81
Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin. Antiviral Res (2011) 0.81
Molecular mechanisms of severe acute respiratory syndrome (SARS). Respir Res (2005) 0.81
Understanding the T cell immune response in SARS coronavirus infection. Emerg Microbes Infect (2012) 0.80
Receptor-binding domain of SARS-Cov spike protein: soluble expression in E. coli, purification and functional characterization. World J Gastroenterol (2005) 0.80
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens. FASEB J (2012) 0.80
Peptide mimicrying between SARS coronavirus spike protein and human proteins reacts with SARS patient serum. J Biomed Biotechnol (2008) 0.78
Antibodies on demand: a fast method for the production of human scFvs with minimal amounts of antigen. BMC Biotechnol (2011) 0.78
SARS-CoV genome polymorphism: a bioinformatics study. Genomics Proteomics Bioinformatics (2005) 0.77
Construction and characterization of single-chain variable fragment antibody library derived from germline rearranged immunoglobulin variable genes. PLoS One (2011) 0.77
Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. MAbs (2010) 0.76
Middle East respiratory syndrome vaccines. Int J Infect Dis (2016) 0.76
Antibody Derived Peptides for Detection of Ebola Virus Glycoprotein. PLoS One (2015) 0.75
Molecular advances in the cell biology of SARS-CoV and current disease prevention strategies. Virol J (2005) 0.75
Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL. MAbs (2016) 0.75
Moonshot Science-Risks and Benefits. MBio (2016) 0.75
SARS patients and need for treatment. Emerg Infect Dis (2004) 0.75
A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med (2003) 29.55
Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med (2003) 27.97
Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science (2003) 18.34
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature (2003) 8.77
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med (1999) 6.91
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet (2003) 6.52
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 6.47
Antibodies, viruses and vaccines. Nat Rev Immunol (2002) 4.92
Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins. Proc Natl Acad Sci U S A (1991) 3.70
The antiviral activity of antibodies in vitro and in vivo. Adv Immunol (2001) 3.29
Coronavirus spike proteins in viral entry and pathogenesis. Virology (2001) 2.85
Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med (1999) 2.53
Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev (2000) 2.38
Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein. J Virol (1994) 2.21
Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med (2003) 2.02
SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest (2003) 1.80
SARS: what have we learned? Nature (2003) 1.79
SARS-associated coronavirus. N Engl J Med (2003) 1.69
Screening of phage antibody libraries. Methods Enzymol (1996) 1.39
In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology (1995) 1.38
Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J Biol Chem (2002) 1.22
Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein. Biochem Biophys Res Commun (2003) 1.16
Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc Natl Acad Sci U S A (1999) 1.11
Antibodies for defense against biological attack. Nat Biotechnol (2002) 1.05
Identification of amino acids involved in a serotype and neutralization specific epitope within the s1 subunit of avian infectious bronchitis virus. Arch Virol (1997) 1.01
Induction of protective immunity in chickens vaccinated with infectious bronchitis virus S1 glycoprotein expressed by a recombinant baculovirus. J Gen Virol (1998) 0.97
Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 31.71
A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med (2003) 29.55
Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science (2003) 18.34
Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol (2009) 12.13
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature (2003) 8.77
The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell (2009) 7.88
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med (2011) 7.29
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A (2012) 6.27
Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis (2002) 6.09
Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA (2005) 5.84
Characterization of human metapneumoviruses isolated from patients in North America. J Infect Dis (2002) 5.64
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife (2012) 5.18
Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A (2004) 5.15
Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe (2009) 5.12
Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science (2005) 4.97
Human metapneumovirus infections in young and elderly adults. J Infect Dis (2003) 4.91
Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep (2004) 3.84
Ecology. North Atlantic right whales in crisis. Science (2005) 3.74
Nipah virus-associated encephalitis outbreak, Siliguri, India. Emerg Infect Dis (2006) 3.65
A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem (2003) 3.60
Angiosperm phylogeny: 17 genes, 640 taxa. Am J Bot (2011) 3.54
Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis (2012) 3.35
Rhinovirus-associated hospitalizations in young children. J Infect Dis (2007) 3.35
H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science (2013) 3.33
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog (2011) 3.26
Rosid radiation and the rapid rise of angiosperm-dominated forests. Proc Natl Acad Sci U S A (2009) 3.22
The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol (2012) 3.17
Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J (2005) 3.14
Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature (2007) 3.06
Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell (2003) 3.03
In search of encephalitis etiologies: diagnostic challenges in the California Encephalitis Project, 1998-2000. Clin Infect Dis (2003) 2.99
Identification of a novel astrovirus (astrovirus VA1) associated with an outbreak of acute gastroenteritis. J Virol (2009) 2.96
T-bet is required for optimal proinflammatory CD4+ T-cell trafficking. Blood (2005) 2.95
Recent resurgence of mumps in the United States. N Engl J Med (2008) 2.90
Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. Emerg Infect Dis (2004) 2.88
Prevalence of viral respiratory tract infections in children with asthma. J Allergy Clin Immunol (2006) 2.67
Human bocavirus: a novel parvovirus epidemiologically associated with pneumonia requiring hospitalization in Thailand. J Infect Dis (2007) 2.65
Genetic characterization of Nipah virus, Bangladesh, 2004. Emerg Infect Dis (2005) 2.62
Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem (2006) 2.56
Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep (2003) 2.53
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol (2002) 2.43
SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J Biol Chem (2005) 2.36
Human metapneumovirus infection among children hospitalized with acute respiratory illness. Emerg Infect Dis (2004) 2.35
Viral respiratory infections in hospitalized and community control children in Alaska. J Med Virol (2010) 2.29
Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. J Virol (2006) 2.20
Evolution of a TRIM5-CypA splice isoform in old world monkeys. PLoS Pathog (2008) 2.20
Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J (2008) 2.15
Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis (2011) 2.12
Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J (2012) 2.12
Sensitive and broadly reactive reverse transcription-PCR assays to detect novel paramyxoviruses. J Clin Microbiol (2008) 2.10
Lower respiratory tract infections among american Indian and Alaska Native children and the general population of U.S. Children. Pediatr Infect Dis J (2005) 2.07
Application of TaqMan low-density arrays for simultaneous detection of multiple respiratory pathogens. J Clin Microbiol (2011) 2.07
Detection of novel SARS-like and other coronaviruses in bats from Kenya. Emerg Infect Dis (2009) 2.04
Global distribution of measles genotypes and measles molecular epidemiology. J Infect Dis (2011) 2.03
Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2012) 1.98
Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog (2012) 1.97
Sequence analysis of the N, P, M and F genes of Canadian human metapneumovirus strains. Virus Res (2003) 1.96
Orthostetrics: Management of Orthopedic Conditions in the Pregnant Patient. Orthopedics (2015) 1.95
Human rhinovirus species associated with hospitalizations for acute respiratory illness in young US children. J Infect Dis (2011) 1.93
Burden of encephalitis-associated hospitalizations in the United States, 1988-1997. Clin Infect Dis (2002) 1.92
Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. J Virol (2006) 1.91
Life expectancy among non-high school graduates. Health Aff (Millwood) (2013) 1.91
Novel human rhinoviruses and exacerbation of asthma in children. Emerg Infect Dis (2008) 1.87
The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe (2013) 1.86
The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res (2005) 1.84
Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general United States infant population. Pediatrics (2004) 1.83
GeneScan reverse transcription-PCR assay for detection of six common respiratory viruses in young children hospitalized with acute respiratory illness. J Clin Microbiol (2003) 1.83
Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor. J Biol Chem (2002) 1.82
Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol (2008) 1.80
Influenza A virus neuraminidase limits viral superinfection. J Virol (2008) 1.79